United Therapeutics
United Therapeutics Corporation, commonly referred to as United Therapeutics, is a pioneering biotechnology company headquartered in the United States. Founded in 1996, the company has established itself as a leader in the development of innovative therapies for patients with chronic and life-threatening conditions, particularly in the field of pulmonary arterial hypertension (PAH). With a strong operational presence across North America and Europe, United Therapeutics focuses on creating unique, life-saving products, including its flagship medications like Remodulin and Tyvaso. These therapies are distinguished by their advanced delivery systems and commitment to improving patient quality of life. Recognised for its significant contributions to the biopharmaceutical industry, United Therapeutics has achieved notable milestones, including the successful development of organ preservation technologies. The company continues to solidify its market position through ongoing research and a dedication to addressing unmet medical needs.
DitchCarbon Score
How does United Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
United Therapeutics's score of 18 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
United Therapeutics's reported carbon emissions
United Therapeutics, headquartered in the US, currently does not provide specific carbon emissions data or reduction targets. Without available figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the company is expected to align with industry standards and best practices regarding climate action. As the pharmaceutical sector increasingly focuses on sustainability, United Therapeutics may be exploring initiatives to reduce its environmental impact, although specific commitments or targets have not been disclosed.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
United Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
